Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abvc Biopharma (ABVC) Total Non-Current Liabilities (2018 - 2025)

Historic Total Non-Current Liabilities for Abvc Biopharma (ABVC) over the last 8 years, with Q3 2025 value amounting to $6.7 million.

  • Abvc Biopharma's Total Non-Current Liabilities rose 399.87% to $6.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.7 million, marking a year-over-year increase of 399.87%. This contributed to the annual value of $114606.0 for FY2024, which is 6699.07% down from last year.
  • Per Abvc Biopharma's latest filing, its Total Non-Current Liabilities stood at $6.7 million for Q3 2025, which was up 399.87% from $6.7 million recorded in Q2 2025.
  • Over the past 5 years, Abvc Biopharma's Total Non-Current Liabilities peaked at $6.9 million during Q1 2025, and registered a low of $32522.0 during Q4 2021.
  • In the last 5 years, Abvc Biopharma's Total Non-Current Liabilities had a median value of $114606.0 in 2024 and averaged $1.8 million.
  • Its Total Non-Current Liabilities has fluctuated over the past 5 years, first tumbled by 9239.68% in 2023, then skyrocketed by 666857.95% in 2025.
  • Abvc Biopharma's Total Non-Current Liabilities (Quarter) stood at $32522.0 in 2021, then skyrocketed by 218.08% to $103447.0 in 2022, then surged by 235.62% to $347193.0 in 2023, then crashed by 66.99% to $114606.0 in 2024, then skyrocketed by 5721.33% to $6.7 million in 2025.
  • Its last three reported values are $6.7 million in Q3 2025, $6.7 million for Q2 2025, and $6.9 million during Q1 2025.